Jones Mitchell Lawrence 4
4 · PALISADE BIO, INC. · Filed Feb 11, 2026
Research Summary
AI-generated summary of this filing
Palisade Bio (PALI) CMO Jones Mitchell Lawrence Receives Award
What Happened
- Jones Mitchell Lawrence, Chief Medical Officer of Palisade Bio, received an award of 787,000 restricted stock units (RSUs) on February 9, 2026. The filing reports an acquisition price of $0.00 because this is a grant of derivative awards (RSUs), not an open‑market purchase or sale.
Key Details
- Transaction date: 2026-02-09; Filing date: 2026-02-11 (filed within the typical 2‑business‑day Form 4 window).
- Award type/code: A (Grant/Award); instrument: Restricted Stock Units (derivative).
- Reported acquisition price: $0.00 (typical for RSU grants).
- Shares owned following the transaction: not specified in the provided filing.
- Notable footnotes:
- F1: Each RSU is a contingent right to one share; until the company has sufficient shares reserved under its 2021 Equity Incentive Plan, RSUs may be settled in cash.
- F2: Vesting schedule: 1/6 of the RSUs vest on July 6, 2026 and then quarterly over the following 10 quarters, subject to continuous service.
Context
- RSU grants are compensation awards and are not direct purchases or sales; they convert to shares (or cash, per F1) upon vesting. This transaction is informational about executive compensation and potential future share issuance rather than an immediate market buy/sell signal.
Insider Transaction Report
Form 4
Jones Mitchell Lawrence
Chief Medical Officer
Transactions
- Award
Restricted Stock Units
[F1][F2]2026-02-09+787,000→ 787,000 total→ Common Stock (787,000 underlying)
Footnotes (2)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock, provided that, until such time as the Issuer has sufficient shares of Issuer common stock reserved under its 2021 Equity Incentive Plan to issue upon settlement of all outstanding grants thereunder, the RSUs may be settled upon vesting in cash.
- [F2]The RSUs shall vest with respect to 1/6th of the shares on July 6, 2026 and quarterly thereafter over the following 10 quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.
Signature
/s/ Ryker Willie, Attorney-in-Fact|2026-02-11